Provided by Tiger Trade Technology Pte. Ltd.

Zentalis Pharmaceuticals, LLC

3.76
-0.0650-1.70%
Post-market: 3.830.0700+1.86%19:30 EDT
Volume:988.68K
Turnover:3.79M
Market Cap:355.97M
PE:-1.92
High:3.96
Open:3.84
Low:3.75
Close:3.83
52wk High:6.95
52wk Low:1.21
Shares:94.67M
Float Shares:76.90M
Volume Ratio:0.72
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9591
EPS(LYR):-1.9100
ROE:-66.75%
ROA:-33.15%
PB:2.48
PE(LYR):-1.97

Loading ...

Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
May 08

BRIEF-Zentalis Pharmaceuticals Announces First Patient Dosed In Aspenova Phase 3 Trial Of Azenosertib In Patients With Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Reuters
·
May 05

Zentalis Pharmaceuticals Inc - Expects Denali Part 2 Topline Readout by Year-End 2026

THOMSON REUTERS
·
May 05

Zentalis grants 26,000 inducement stock options at $4.09 per share

Reuters
·
May 02

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 02

Zentalis Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
May 01

Zentalis to present phase 1b azenosertib-paclitaxel data in ovarian cancer at ASCO

Reuters
·
Apr 21

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

TIPRANKS
·
Apr 18

Zentalis presents azenosertib preclinical TNBC combination data at AACR 2026

Reuters
·
Apr 18

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News

Simply Wall St.
·
Apr 13

What's Behind The Surge In Zentalis Stock?

Benzinga_recent_news
·
Apr 11

Zentalis Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 10

H.C. Wainwright Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
Apr 10

Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials

Reuters
·
Apr 09

Zentalis Pharmaceuticals Inc - Denali Part 2 Topline Readout Expected by Year-End 2026

THOMSON REUTERS
·
Apr 09

Zentalis Pharmaceuticals Announces 400Mg Qd 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 09

BRIEF-Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 02

Zentalis grants inducement stock options for 36,000 shares to new hires

Reuters
·
Apr 02

Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
Mar 28

Zentalis Pharmaceuticals Price Target Maintained With a $6.00/Share by Guggenheim

Dow Jones
·
Mar 27